GRACEcast Lung Cancer Audio podcast

Angiogenesis, the Sequel: Does Cyramza (Ramucirumab) Make a Difference for Second Line Treatment?

0:00
7:28
15 Sekunden vorwärts
15 Sekunden vorwärts

The REVEL trial studied 1,200 non-small cell lung cancer patients to see if the drug Cyramza (ramucirumab) improved overall surival. The doctors had mixed feelings about the results.

Weitere Episoden von „GRACEcast Lung Cancer Audio“